NYSE:JNJPharmaceuticals
Assessing Johnson & Johnson (JNJ) Valuation After Autoimmune Pipeline Advances And New R&D Partnership
Johnson & Johnson (JNJ) is in focus after two recent autoimmune updates, positive 52 week Phase 3 results for oral psoriasis drug ICOTYDE, and a US$500 million R&D partnership with Royalty Pharma on antibody therapy JNJ-4804.
See our latest analysis for Johnson & Johnson.
Against this backdrop of autoimmune pipeline news, Johnson & Johnson’s share price has climbed 19.0% over the past 90 days and 17.2% year to date, contributing to a 63.0% total shareholder return over twelve months that...